OBJECTIVE： To compare clinical efficacy and safety of 0.9％ and 3％ Sodium chloride solution for atomization inhalation therapy in children with asthmatic pneumonia. METHODS： 150 children with asthmatic pneumonia were selected and randomly divided into group A and B with 75 cases in each group. Both group received atomization regimen of Compound ipratropium bromide+budesonide+terbutaline； group A was given 0.9％ Sodium chloride solution as solvent， and group B was given 3％ Sodium chloride solution as solvent. Clinical efficacy， clinical symptom and sign disappearance time， hospitalization time were observed in 2 groups， and clinical severity score， respiratory rate and oxygen saturation level were also observed before and after treatment； the incidence of ADR was compared. RESULTS： The clinical efficacy of group B was significantly better than that of group A（94.12％ vs. 83.53％）， with statistical significance （P＜0.05）. The time of symptom and sign disappearance and hospitalization time of group B were significantly shorter than those of group A， with statistical significance（P＜0.05）. Before treatment， there was no statistical significance in clinical severity score， respiratory rate and oxygen saturation level between 2 groups （P＞0.05）. After treatment， clinical severity score， respiratory rate and oxygen saturation level of group B was significantly better than those of group A， with statistical significance （P＜0.05）. There was no statistical significance in the incidence of ADR between 2 groups （P＞0.05）. CONCLUSIONS： 3％ Sodium chloride solution as solvent is suitable for atomization inhalation therapy in children with asthmatic pneumonia and doesn’t increase ADR.